REDHILL BIOPHARMA LTD-SP ADR (RDHL)
US7574682024 - ADR
We assign a fundamental rating of 3 out of 10 to RDHL. RDHL was compared to 198 industry peers in the Pharmaceuticals industry. RDHL has a medium profitability rating, but doesn't score so well on its financial health evaluation. While showing a medium growth rate, RDHL is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year RDHL was profitable.
In the past year RDHL has reported a negative cash flow from operations.
In the past 5 years RDHL reported 4 times negative net income.
In the past 5 years RDHL always reported negative operating cash flow.
1.2 Ratios
RDHL has a Return On Assets of 103.77%. This is amongst the best in the industry. RDHL outperforms 100.00% of its industry peers.
Looking at the Return On Equity, with a value of 1155.92%, RDHL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 262.27%, RDHL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 103.77% | ||
| ROE | 1155.92% | ||
| ROIC | 262.27% |
ROA(3y)1.58%
ROA(5y)-18.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RDHL has a Profit Margin of 366.25%. This is amongst the best in the industry. RDHL outperforms 99.49% of its industry peers.
RDHL's Operating Margin of 193.45% is amongst the best of the industry. RDHL outperforms 100.00% of its industry peers.
RDHL's Gross Margin of 47.03% is in line compared to the rest of the industry. RDHL outperforms 59.69% of its industry peers.
In the last couple of years the Gross Margin of RDHL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 193.45% | ||
| PM (TTM) | 366.25% | ||
| GM | 47.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.3%
GM growth 5Y-6.56%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RDHL is creating value.
RDHL has more shares outstanding than it did 1 year ago.
RDHL has more shares outstanding than it did 5 years ago.
RDHL has a better debt/assets ratio than last year.
2.2 Solvency
RDHL has an Altman-Z score of -22.51. This is a bad value and indicates that RDHL is not financially healthy and even has some risk of bankruptcy.
RDHL has a Altman-Z score of -22.51. This is amonst the worse of the industry: RDHL underperforms 85.71% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that RDHL is not too dependend on debt financing.
RDHL has a Debt to Equity ratio (0.22) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.51 |
ROIC/WACC90.75
WACC2.89%
2.3 Liquidity
RDHL has a Current Ratio of 0.84. This is a bad value and indicates that RDHL is not financially healthy enough and could expect problems in meeting its short term obligations.
RDHL's Current ratio of 0.84 is on the low side compared to the rest of the industry. RDHL is outperformed by 90.82% of its industry peers.
A Quick Ratio of 0.61 indicates that RDHL may have some problems paying its short term obligations.
RDHL's Quick ratio of 0.61 is on the low side compared to the rest of the industry. RDHL is outperformed by 90.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
RDHL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 107.69%, which is quite impressive.
Looking at the last year, RDHL shows a very negative growth in Revenue. The Revenue has decreased by -89.43% in the last year.
RDHL shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.82% yearly.
EPS 1Y (TTM)107.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q192.3%
Revenue 1Y (TTM)-89.43%
Revenue growth 3Y-53.36%
Revenue growth 5Y-4.82%
Revenue growth Q2Q-48.98%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
RDHL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.11% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year131.11%
Revenue Next 2Y105.48%
Revenue Next 3Y77.82%
Revenue Next 5Y63.11%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 0.51, the valuation of RDHL can be described as very cheap.
RDHL's Price/Earnings ratio is rather cheap when compared to the industry. RDHL is cheaper than 100.00% of the companies in the same industry.
RDHL is valuated cheaply when we compare the Price/Earnings ratio to 24.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.51 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RDHL is valued cheaply inside the industry as 98.98% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.48 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
RDHL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REDHILL BIOPHARMA LTD-SP ADR
NASDAQ:RDHL (4/18/2024, 1:06:32 PM)
0.4098
+0.02 (+6.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.17M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.51 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 103.77% | ||
| ROE | 1155.92% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 193.45% | ||
| PM (TTM) | 366.25% | ||
| GM | 47.03% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)107.69%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-89.43%
Revenue growth 3Y-53.36%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y